Relapsed Refractory Multiple Myeloma Rrmm Breakout Session Doris Hansen Md Tampa Rt

Media Summary: Watch the full course and our most up-to-date content here: Create a free account to track ...

Relapsed Refractory Multiple Myeloma Rrmm Breakout Session Doris Hansen Md Tampa Rt - Detailed Analysis & Overview

Watch the full course and our most up-to-date content here: Create a free account to track ...

Photo Gallery

$Relapsed/Refractory Multiple Myeloma (RRMM) Breakout Session | Doris Hansen, MD | Tampa RT$

Doris Hansen, MD on predictors of early relapse following ciltacabtagene autoleuce in RRMM

$CAR-T Cell Therapy Cilta-cel for Relapsed/Refractory Myeloma | Doris Hansen, MD | ASCO 2023$

Doris Hansen, MD: CAR T-cell & bispecific antibody therapies in multiple myeloma

Safety and efficacy of cilta-cel in RRMM: a CIBMTR study

Drs. Kedar Kirtane and Doris Hansen on Advances in Multiple Myeloma Treatment

Dr. Doris Hansen at ASCO 2023: Abstract No. 8012

What is considered an "optimal" response when treating a patient with myeloma with CAR-T?

Treatment patterns and outcomes in patients with quad-class-exposed RRMM

$ASH 2024: Doris Hansen, MD on Ide and Cilta-cel in Relapsed/Refractory Multiple Myeloma$

Doris Hansen, MD: Bridging response, low burden improve cilta-cel outcomes in MM

Doris Hansen, MD: Real-world non-ICANS neurologic events with cilta-cel in myeloma

View Detailed Profile

Relapsed/Refractory Multiple Myeloma (RRMM) Breakout Session | Doris Hansen, MD | Tampa RT

Relapsed/Refractory Multiple Myeloma (RRMM) Breakout Session | Doris Hansen, MD | Tampa RT

Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity Create a free account to track ...

Doris Hansen, MD on predictors of early relapse following ciltacabtagene autoleuce in RRMM

Doris Hansen, MD on predictors of early relapse following ciltacabtagene autoleuce in RRMM

From #ASH25:

CAR-T Cell Therapy Cilta-cel for Relapsed/Refractory Myeloma | Doris Hansen, MD | ASCO 2023

CAR-T Cell Therapy Cilta-cel for Relapsed/Refractory Myeloma | Doris Hansen, MD | ASCO 2023

Interview with

Doris Hansen, MD: CAR T-cell & bispecific antibody therapies in multiple myeloma

Doris Hansen, MD: CAR T-cell & bispecific antibody therapies in multiple myeloma

From #ASH25:

Safety and efficacy of cilta-cel in RRMM: a CIBMTR study

Safety and efficacy of cilta-cel in RRMM: a CIBMTR study

Doris Hansen

Drs. Kedar Kirtane and Doris Hansen on Advances in Multiple Myeloma Treatment

Drs. Kedar Kirtane and Doris Hansen on Advances in Multiple Myeloma Treatment

At #CellCoast25, Kedar Kirtane,

Dr. Doris Hansen at ASCO 2023: Abstract No. 8012

Dr. Doris Hansen at ASCO 2023: Abstract No. 8012

At ASCO 2023:

What is considered an "optimal" response when treating a patient with myeloma with CAR-T?

What is considered an "optimal" response when treating a patient with myeloma with CAR-T?

In this video,

Treatment patterns and outcomes in patients with quad-class-exposed RRMM

Treatment patterns and outcomes in patients with quad-class-exposed RRMM

Doris Hansen

ASH 2024: Doris Hansen, MD on Ide and Cilta-cel in Relapsed/Refractory Multiple Myeloma

ASH 2024: Doris Hansen, MD on Ide and Cilta-cel in Relapsed/Refractory Multiple Myeloma

Doris Hansen

Doris Hansen, MD: Bridging response, low burden improve cilta-cel outcomes in MM

Doris Hansen, MD: Bridging response, low burden improve cilta-cel outcomes in MM

At #ASH25,

Doris Hansen, MD: Real-world non-ICANS neurologic events with cilta-cel in myeloma

Doris Hansen, MD: Real-world non-ICANS neurologic events with cilta-cel in myeloma

Tune in from #ASH25 as

Pre-treatment biomarkers associated with toxicity and responses in R/R myeloma treated with ide-cel

Pre-treatment biomarkers associated with toxicity and responses in R/R myeloma treated with ide-cel

Doris Hansen

Dr. Doris Hansen at ASCO 2022: Abstract No. 8042

Dr. Doris Hansen at ASCO 2022: Abstract No. 8042

Dr

Dr. Doris Hansen at TANDEM 2023: Abstract 256

Dr. Doris Hansen at TANDEM 2023: Abstract 256

LIVE from Orlando:

Real-world experiences with ide-cel in R/R multiple myeloma

Real-world experiences with ide-cel in R/R multiple myeloma

Doris Hansen

Optimizing bridging therapy prior to CAR T-cell therapy in multiple myeloma

Optimizing bridging therapy prior to CAR T-cell therapy in multiple myeloma

Doris Hansen

Myeloma Now: Insights and Innovations

Myeloma Now: Insights and Innovations

Explore the evolving

Charting the Path Forward in Multiple Myeloma Care | Doris Hansen, MD | Tampa RT

Charting the Path Forward in Multiple Myeloma Care | Doris Hansen, MD | Tampa RT

Watch the full course and our most up-to-date content here: https://linktr.ee/HealthTreeUniversity Create a free account to track ...

Strategies being explored to optimize CAR T-cell therapy for high-risk multiple myeloma

Strategies being explored to optimize CAR T-cell therapy for high-risk multiple myeloma

In this video,